Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
- Conditions
- Lymphoma, Non-Hodgkin
- Registration Number
- NCT00045864
- Lead Sponsor
- Chiron Corporation
- Brief Summary
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with intermediate-and high- grade Non-Hodgkin's lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (33)
ACRC/Arizona Clinical Research Center, Inc.
🇺🇸Tucson, Arizona, United States
Hoag Cancer Center
🇺🇸Newport Beach, California, United States
UC Davis Cancer Center
🇺🇸Sacramento, California, United States
John Wayne Cancer Institute
🇺🇸Santa Monica, California, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
California Cancer Medical Center
🇺🇸West Covina, California, United States
Georgetown University Medical Center, Lombardi Cancer Center
🇺🇸Washington, District of Columbia, United States
Washington Cancer Institute
🇺🇸Washington, District of Columbia, United States
Division of Hematology/Oncology, University of Miami School of Medicine
🇺🇸Miami, Florida, United States
Northwestern University, Feinberg School of Medicine
🇺🇸Chicago, Illinois, United States
Scroll for more (23 remaining)ACRC/Arizona Clinical Research Center, Inc.🇺🇸Tucson, Arizona, United States